Lymphodrugs in postmastectomy lymphedema: Systematic review;Linfofármacos en el linfedema postmastectomía: Revisión sistemática

Rehabilitacion

Volumn 40, Issue 2, 2006, Pages 86-95

  Calderón González, Antonio María ^a,c   Cecilio Montero, F J ^b   Rodriguez Cerdeira C ^a   Caeiro Munoz M ^a  

^a Servicio Gallego de Salud   (Spain)

^b Servicio Gallego de Salud   (Spain)

^c HOSPITAL DO MEIXOEIRO   (Spain)

Author keywords

Lymphedema; Lymphodrugs; Mastectomy

Indexed keywords

EID: 34547866263     PISSN: 00487120     EISSN: 15783278     Source Type: Journal    
DOI: 10.1016/S0048-7120(06)74867-8     Document Type: Review

References (47)

1. Ospina MB, Gómez C. Systematic reviews of literature in health. Rev Colomb Neumol. 2001;13:109-14.
2. Avellanet Viladomat M, González Viejo MA, Condón Huerta MJ, Sáenz Guerrero A. Linfedema secundario a linfadenectomía axilar: concepto y valoración. Rehabilitación (Madr). 2003;37:215-21.
3. Forner Cordero I, Maldonado Garrido D, Muñoz Langa J. Necesidad de información para la prevención del linfedema postmastectomí a. Rehabilitación (Madr). 2003;37:141-4.
4. Romero Cullerés G, Almendáriz Juárez A. Linfedema después de la cirugía por cáncer de mama. Estudio de la incidencia y factores de riesgo en 113 pacientes. Rehabilitación (Madr). 2004;38:72-7.
5. Rinehart-Ayres ME. Conservative approaches to lymphedema treatment. Cáncer. 1998;83:2828-32.
6. González Viejo MA, Condón Huerta MJ, Lecuona Navea M, Val Lampreave L, Laínez Zaragüeta I, Rezusta Sagasti L, et al. Coste-efectividad del tratamiento del linfedema postmastectomía en España. Rehabilitación (Madr). 2001;35:68-73.
7. Laustalet R. Linfotropos. Farmacoterapia venolinfática. En: Cubría Mirapeix JM, Honorato Pérez J. Barcelona: Laboratorios FAES; 1997. p. 193-205.
8. Ramalet AA. Pharmacologic aspects of a phlebotropic drug in CVI - associated edema. Angiology. 2000;51:19-23.
9. Cuello Villaverde E, Guerola Soler H, López Rodríguez A. Perfil clínico y terapéutico del linfedema postmastectomía. Rehabilitación (Madr). 2003;37:22-32.
10. Casley-Smith JR. Benzo-pyrones in the treatment of lymphoedema. Int Angiol. 1999;18:31-41.
11. Casley-Smith JR, Morgan RG, Piller NB. Treatment of lymphedema of the arms and legs with 5,6-benzo-(alpha) pyrone. N Engl J Med. 1993;329: 1158-63.
12. Pflug JJ. Medikamentöse. Therapie des chronish geschowllenen Beines. Folia Angiol. 1976;24:78-81.
13. Piller NB, Morgan RG, Casley-Smith JR. A double blind cross-over trial of O-(B-hydroxy-ethyl)-rutosides (benzo-pirones) in the treatment of lymphoedema of the arms and legs. Br J Plastic Surg. 1988;41:20-7.
14. Taylor UM, Rose KE, Twycross RG. A double blind clinical trial of hidroxy-ethylrutosides in obstructive arm lymphoedema. Phlebology. 1993;1:22-8.
15. Casley-Smith JR, Jamal S, Casley-Smith J. Treatment of filarial lymphoedema and elephantiasis with 5,6-benzo-(alpha) pyrone. Br Med J. 1993;307:1037-41.
16. Casley-Smith JR, Wang CT, Casley-Smith J. Reduction of filaritic lymphoedema and elephantiasis with 5,6-benzo-(alpha) pyrone (coumarin), and the effects of diethylcarbamazine (DEC). Ann Trop Med Parasitol. 1993;87:247-58.
17. Chang TS, Gan JI, Fu KD, Huang WY. The use of 5,6-benzo-(alpha) pyrone and heating by microwaves in the treatment of chronic lymphedema of the legs. Lymphology. 1996; 29:106-11.
18. Cluzan R, Pecking A. Benzopyrone (Lysedem) double blind crossing over study in patients with secondary upper limb edemas. Progress in lymphology XII: proceedings of the XIIth International Congress of Lymphology, ICS887; 1990. p. 453-4.
19. Desprez-Curely JP, Cluzan R, Pecking A. Benzopyrones and postmastectomy lymphoedemas. Double blind trial placebo versus sustained release coumarin with trioxyethylrutin (TER). En: Casley-Smith JR, Piller NB. editors. Progress in Lymphology - X. Adelaide: Univ Adel Press, 1985. p. 203-5.
20. Mortimer PS, Badger C, Clarke I, Pallett J. A double blind, randomized, parallel group, placebo-controlled trial of O-(B-hydroxy-ethyl)-rutosides in chronic arm oedema resulting from breast cancer treatment. Phlebology. 1995;10:51-5.
21. Casley-Smith JR, Jamal S, Casley-Smith J. Teatment of lymphedema by complex physical therapy with and without oral and topical benzo-pyrones: what should therapists and patients expect. Lymphology. 1996;29:20-3.
22. Lafontan B, Dylhuydy JM, Monnier A. Contribution of coumarin associated with physiotherapy in the treatment of lymphedema of the arm after breast cancer: A one year study. Bull Cancer/ Radiother. 1991;78:119-21.
23. Loprinzi CL, Kugler JW, Sloan JA, Rooke TW, Quella SK, Novotny P, et al. Lack of effect of coumarin in women with lymphedema after treatment for breast cancer. N Engl J Med. 1999;340:346-50.
24. Pecking AP. Efficacy of Daflon 500 mg in the treatment of lymphedema (secondary to conventional therapy of breast cancer). Angiology. 1997;48:93-8.
25. Cluzan RV, Alliot F, Ghabboun S, Pascot M. Treatment of secondary lymphedema of the upper limb with CICLO 3 FORT. Lymphology. 1996;29:29-35.
26. Piller NB, Clodius L. Clinical result of the effectiveness of Venalot in 103 postlymphoedema patients. En: Bartos V, Davidson JW, editors. Advances in lymphology. Prague: Avicenum; 1985. p. 475-9.
27. De Lafontan B, Dilhuydy JM, Monnier A, Ciupa M, Leutenegger E, Goehrs JM. Interés de la cumarina asociada a la fisioterapia en el tratamiento de linfedema de miembro superior consecutivo a cáncer de mama: estudio de 1 año de duración. Bull Cancer/Radiother. 1991:78;119-24.
28. Pecking AP. Evaluation by lymphoscinigraphy of a micronized flavonoide fraction (S 5682) in the treatment of upper limb lymphedema. Int Angiol. 1996;14:39-43.
29. Clodius L, Piller NB. The conservative treatment of post mastectomy in patients with coumarin results in a marked continuous reduction in swelling. En: Bartos V, Davidson JW, editors. Advances in lymphology. Prague: Avicenum; 1982. p. 471-4.
30. Clodius L, Piller NB. Conservative therapy for postmastectomy lymphedema. Chirurgia Plastic. 1978;4:193-202.
31. Loprinzi CL, Kugler JW, Sloan JA, Rooke TW, Quella SK, Novotny P, et al. Lack of efecct of coumarin in women with lymphedema after treatment for breast cancer. N Engl J Med. 1999;340:346-50.
32. Burgos A, Alcaide A, Alcoba C, Azcona JM, Garrido J, Lorente C, et al. Comparative study of the clinical efficacy of two different coumarin dosages in the management of arm lymphedema after treatment for breast cancer. Lymphology. 1999;32:1-2.
33. Soler Fernández A, Serra Escorihuela M, Rojas del Castillo C, Bastos Pineheiro N, Ruiz A. Hidrosmine associated to measures physics and control guideline in 20 lymphedema postmastectomy: Results after one year of treatment. Angiology. 1998;49:36-40.
34. Jiménez Cossío JA, Magallón Ortín P, Valiente Domingo R. Acción terapéutica de hidrosmina en el linfedema crónico. Angiología. 1991;43:93-7.
35. Olszewski W. Clinical efficacy of micronized purified flavonoid fraction (MPFF) in edema. Angiology. 2000;51:25-9.
36. Expert-reviewed information summary about the treatment of lymphedema. (Consultado el 27/09/2004). Disponible en: http://www. cancer. gov/doc-pdq.aspx?viewid.
37. Casley-Smith JR, Casley-Smith J. Lymphoedema therapy in Australia; complex physical therapy, exercises & benzo-pyrones, on over 600 limbs. (Consultado el 17/06/2004). Disponible en http://www.lymphoedema.org.au/618- limb.htm.
38. Loprinzi Cl, Sloan J, Kugler J. Coumarin-induced hepatoxicity. J Clin Oncol. 1997;15:3167-8.
39. Cancellation of registration (from the Australian Department of Health and Family Services, August 1996). Lymphovenous Canada: Health Watch. (Consultado el 18/06/2004). Disponible en: http://www.lymphovenouscanada.ca/ watchcou.htm.
40. Lymphovenous Canada: liver toxicity raises doubts about coumarin. (Consultado el 1/07/2004). Disponible en: http://www.lymphovenous-Canada.ca/ benzo.htm.
41. Harris SR, Hugi MR, Olivotto IO, Levine M. Clinical practice guidelines for the care treatment of breast cancer: 11. Lymphedema. Canadian Medical Association Journal. 2001;164:191-9.
42. British Lymphology Society. Strategy for lymphoedema care. (Consultado el 18/06/2004). Disponible en http://www.sefh.lymphoedema.org/bls/blss0010.htm.
43. Lymphoedema Support Network. Lymphedema awareness: before, during and after breast cancer. (Consultado el 18/06/2004). Disponible en: http://www.lymphoedema.org/lsn/lsn010.htm.
44. Alertas de Farmacovigilancia. Comunicación sobre riesgos de medicamentos para profesionales sanitarios. Nota informativa: re-evaluación de la relación beneficio-riesgo de los agentes linfofármacos para administración oral. Ref.2002/09 (5 de septiembre de 2002). (Consultado el 18/03/2004). Disponible en http://www.sefh.es/alertas/flebotonicos.htm.
45. Howell D, Ezzo J, Tuppo K, Bily L, Johannson K. Complete decongestive therapy for lymphedema following breast cancer treatment (protocol for a Cochrane Review). The Cochrane Library, Issue 2, 2003. Oxford: Update Software.
46. Kligman L, Wong RK, Johnston M, Laetsch NS. The treatment of lymphoedema related to breast cancer: a systematic review and evidence summary. Support Care Cancer. 2004;12:421-31.
47. Badger C, Preston N, Seers K, Mortimer P. Benzopyrones for reducing and controlling lymphoedema limbs. Cochrane Database Syst Rev. 2004;(2):CD003140.